Education
About Us
Working with TipRanks
Follow Us
CytoDyn (CYDY)
:CYDY
CYDY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.10 - $0.49
Previous CloseN/A
Volume1.91M
Average Volume (3M)3.30M
Market Cap
$287.60M
Enterprise ValueN/A
Total Cash (Recent Filing)$21.34M
Total Debt (Recent Filing)$46.08M
Price to Earnings (P/E)―
Beta0.47
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,227,737,400
10 Day Avg. Volume1,465,745
30 Day Avg. Volume3,299,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
5.11%
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
94.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CYDY FAQ
What was CytoDyn’s price range in the past 12 months?
CytoDyn lowest stock price was $0.10 and its highest was $0.49 in the past 12 months.
What is CytoDyn’s market cap?
CytoDyn’s market cap is $287.60M.
When is CytoDyn’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoDyn’s earnings last quarter?
Currently, no data Available
Is CytoDyn overvalued?
According to Wall Street analysts CytoDyn’s price is currently Overvalued.
Does CytoDyn pay dividends?
CytoDyn does not currently pay dividends.
What is CytoDyn’s EPS estimate?
CytoDyn’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoDyn have?
CytoDyn has 1,227,737,400 shares outstanding.
What happened to CytoDyn’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoDyn?
Currently, no hedge funds are holding shares in CYDY
---
CytoDyn Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
169.23%
Trailing 12-Months
Company Description
CytoDyn
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
---
CYDY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---